

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

4121-133

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

**10/031505**

INTERNATIONAL APPLICATION NO.

PCT/DE00/02346

INTERNATIONAL FILING DATE

14 July 2000

PRIORITY DATE CLAIMED

16 July 1999

TITLE OF INVENTION

CONJUGATE FOR MEDIATING CELL-SPECIFIC, COMPARTMENT-SPECIFIC OR MEMBRANE-SPECIFIC TRANSPORT OF ACTIVE SUBSTANCES

APPLICANT(S) FOR DO/EO/US

BRAUN, Klaus; PESCHKE, Peter; FRIEDRICH, Eckart; PIPKORN, Rudiger; WALDRECK, Waldemar and DEBUS, Jurgun

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:


1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).\*(**Unsigned**)
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. to 16. below concern other document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☒ A small entity statement.
16. ☒ Other items or information: Sequence Listing and Computer Readable Disk containing same.

NOTE: This application is being filed with an unsigned Oath or Declaration under the provisions of 37 CFR § 1.53 in order that applicants may secure a filing date of January 15, 2002. Upon receipt of a "Notice to File Missing Parts - Filing Date Granted," an executed Declaration and Power of Attorney, will be filed in the Patent and Trademark Office. The undersigned agent affirmatively states that she has been duly authorized and appointed to file this application on behalf of the applicants and that the Declaration and Power of Attorney to be filed hereafter will confirm the undersigned agent's authorization and appointment. Applicants are entitled to small entity status within the meaning of 37 CFR § 1.9.

100-1031505

				CALCULATIONS	PTO USE ONLY
17. <input checked="" type="checkbox"/> The following fees are submitted: <b>Basic National Fee</b> (37 CFR 1.492(a)(1)-(5)) Search Report has been prepared by the EPO or JPO .....\$860.00				531 Rec'd PCT/P. 15 JAN 2002	
International preliminary examination fee paid to USPTO (37 CFR 1.482) .....\$0.00					
No International preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....\$0.00					
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....\$1000.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....\$0.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$ 860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	18-20 =	0	X \$18.00	\$	
Independent Claims	1- 3 =	0	X \$80.00	\$	
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				860.00	
Reduction by 1/2 for filing by small entity, if applicable Verified Small Entity statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$ 430.00	
<b>SUBTOTAL =</b>				\$ 430.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 Months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>				\$ 430.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)) The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
<b>TOTAL FEE ENCLOSED =</b>				\$ 430.00	
				<b>Amount to be refunded</b>	\$
				<b>Charged</b>	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$430.00 to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 08-3284. A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not yet been met, a petition to revive (37 CFR 1.127(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO:					
Steven J. Hultquist				MARIANNE FUIERER	
Intellectual Property/Technology Law				Registration No. 39,983	
P. O. Box 14329					
Research Triangle Park, NC 27709					

10021505 670207  
10/031505  
531 Rec'd PCT/PTC 15 JAN 2002

4121-133  
PATENT APPLICATION

---

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**In re Application of:** Klaus Braun, et al.

**Application No.:** New U.S. National Stage Application of  
PCT International Application No. PCT/DE00/02346

**International Filing Date:** 14 July 2000

**Priority Date Claimed:** 16 July 1999 (German Appl. No. 199 33 492.7)

**U.S. National Phase Filing Date:** Date of mailing identified below

**Title:** **CONJUGATE FOR MEDIATING CELL-  
SPECIFIC, COMPARTMENT-SPECIFIC OR  
MEMBRANE SPECIFIC TRANSPORT OF  
ACTIVE SUBSTANCES**


---

**EXPRESS MAIL CERTIFICATE**

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to the Commissioner for Patents, Box Patent Application, Washington, DC 20231, and Express Mailed under the provisions of 37 CFR 1.10.

Blake Crouch

\_\_\_\_\_  
Name of Person Mailing This Document

  
\_\_\_\_\_  
Signature

January 15, 2002

\_\_\_\_\_  
Date

EV037733335US

\_\_\_\_\_  
Express Mail Label Number

---

**PRELIMINARY AMENDMENT**

---

Commissioner for Patents  
BOX PATENT APPLICATION  
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified new national phase patent application, please amend the application, as follows:

**In the Specification**

Please insert on page 1, between the title of the application and the first paragraph, the following new paragraph:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is filed under the provisions of 35 U.S.C. §371 and claims the priority of International Patent Application No. PCT/DE00/02346 filed July 14, 2000, which in turn claims priority of German Patent Application No. 199 33 492.7 filed July 16, 1999.

**In the Claims**

Please amend claims 3, 5, 7-9, 11 -12, 14-15 and 17 to read as follows:

3. The conjugate according to claim 1, wherein the transport mediator is a member selected from the group consisting of: a penetratin, a penetratin derivative, transportan or parts thereof, bacterial transport protein and viral transport protein.

5. The conjugate according to claim 1, wherein the cell-specific, compartment-specific or membrane-specific address protein or peptide is selected from the group consisting of:

for import into the ER                      H<sub>3</sub>N<sup>+</sup>-Net-Met-Ser-Phe-Val-

Ser-Leu-Leu-Leu-Val-Gly-  
Ile-Leu-Phe-Trp-Ala-Thr-  
Clu-Ala-Clu-Gln-Leu-Thr-  
Lys-Cys-Glu-Val-Phe-Gln;

for reimport into the ER H<sub>2</sub>N-Lys-Asp-Glu-Leu-COO<sup>-</sup>;

for import into mitochondria H<sub>3</sub>N<sup>+</sup>-Met-Leu-Ser-Leu-Arg-  
Gln-Ser-Ile-Arg-Phe-Phe-  
Lys-Pro-Ala-Thr-Arg-Thr-  
Leu-Cys-Ser-Ser-Arg-Tyr-  
Leu-Leu;

for import into the nucleus -Pro-Pro-Lys-Lys-Lys-Arg-Lys-  
Val

H<sub>3</sub>N<sup>+</sup>-Pro-Lys-Lys-Lys-Arg  
Lys-Val-(= nuclear  
localization sequence from  
SV4Q-T antigen);

for import into peroxisomes H<sub>2</sub>N-Ser-Lys-Leu-COO<sup>-</sup>;and

for binding to cell membrane H<sub>3</sub>N<sup>+</sup>-Gly-Ser-Ser-Lys-Ser-Lys-  
Pro-Lys.

7. The conjugate according to claim 1, wherein the active substance is selected from the group consisting of nucleic acids, proteins/peptides and/or chemical substances.

8. The conjugate according to claim 1, wherein the conjugate has the following structure:

transport mediator - address protein - active substance

9. The conjugate according to claim 1, wherein a spacer is also present, if applicable.

11. The conjugate according to claim 9, wherein the spacer is a member selected from the group consisting of: polylysine, polyethylene glycol or polyvinyl pyrrolidone.

12. A method of preparing a conjugate according to claim 1, comprising the steps of:

- 1) synthesizing separate peptides of "P", "AP",
- 2) forming a covalent bond between "AP" and active substance,
- 3) redox coupling of the product from step 2) with "P" by means of redox coupling.

14. The method according to claim 12, wherein the redox coupling is carried out in an aqueous DMSO solution.

15. The method according to claim 14, wherein a further purification step follows.

17. Use of a conjugate according to claim 1 for the cell-specific, compartment-specific or membrane-specific transport of a desired active substance.

Please add new claim 19.


19. The method according to claim 12, further comprising:  
synthesizing a spacer to be covalently bonded between "AP"  
and active substance.

#### REMARKS

A marked-up version of amended claims is included herewith in Appendix A and a clean copy of all pending claims is included in Appendix B.

It is requested that the examination and prosecution of this application proceed on the basis of these amended claims 1-19.

Respectfully submitted,



Marianne Fuierer  
Registration No. 39,983  
Attorney for Applicants

INTELLECTUAL PROPERTY/  
TECHNOLOGY LAW  
P. O. Box 14329  
Research Triangle Park, NC 27709  
Phone: (919) 419-9350  
Fax: (919) 419-9354  
Attorney File: 4121-133

531 Rec'd PCT/PTC 15 JAN 2002

## APPENDIX A

**In the Specification**

Please insert on page 1, between the title of the application and the first paragraph, the following new paragraph:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is filed under the provisions of 35 U.S.C. §371 and claims the priority of International Patent Application No. PCT/DE00/02346 filed July 14, 2000, which in turn claims priority of German Patent Application No. 199 33 492.7 filed July 16, 1999.

**In the Claims**

Please amend claims 3, 5, 7-9, 11 -12, 14-15 and 17 to read as follows:

3. The conjugate according to claim 1 [or 2], wherein the transport mediator is a member selected from the group consisting of: a penetratin, a penetratin derivative, transportan or parts thereof, bacterial transport protein and [derived from the penetratin family or is transportan or parts thereof or is a bacterial or] viral transport protein.

5. The conjugate according to claim 1 [any one of the preceding claims], wherein the cell-specific, compartment-specific or membrane-specific address protein or peptide is selected from the group consisting of:



for import into the ER	H <sub>3</sub> N <sup>+</sup> -Net-Met-Ser-Phe-Val-Ser-Leu-Leu-Leu-Val-Gly-Ile-Leu-Phe-Trp-Ala-Thr-Clu-Ala-Clu-Gln-Leu-Thr-Lys-Cys-Glu-Val-Phe-Gln; <u>i</u>
for reimport into the ER	H <sub>2</sub> N-Lys-Asp-Glu-Leu-COO <sup>-</sup> ; <u>i</u>
for import into mitochondria	H <sub>3</sub> N <sup>+</sup> -Met-Leu-Ser-Leu-Arg-Gln-Ser-Ile-Arg-Phe-Phe-Lys-Pro-Ala-Thr-Arg-Thr-Leu-Cys-Ser-Ser-Arg-Tyr-Leu-Leu; <u>i</u>
for import into the nucleus	-Pro-Pro-Lys-Lys-Lys-Arg-Lys-Val
	H <sub>3</sub> N <sup>+</sup> -Pro-Lys-Lys-Lys-Arg-Lys-Val-(= nuclear localization sequence from SV4Q-T antigen); <u>i</u>
for import into peroxisomes	H <sub>2</sub> N-Ser-Lys-Leu-COO <sup>-</sup> ; <u>i</u> and
for binding to cell membrane	H <sub>3</sub> N <sup>+</sup> -Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-.

7. The conjugate according to claim 1 [any one of the preceding claims, wherein the active substance is selected from the group consisting of nucleic acids, proteins/peptides and/or chemical substances.

8. The conjugate according to claim 1 [any one of the preceding claims], wherein the conjugate has the following structure:

transport mediator - address protein - active substance

9. The conjugate according to claim 1 [any one of the preceding claims], wherein a spacer is also present, if applicable.

11. The conjugate according to claim 9 [or 10], wherein the spacer is a member selected from the group consisting of: polylysine, polyethylene glycol or polyvinyl pyrrolidone.

12. A method of preparing a conjugate according to claim 1 [any one of claims 1 to 11], comprising the steps of:

- 1) synthesizing separate peptides [synthesis] of "P", "AP"[, and the spacer, if applicable],
- 2) forming a covalent bond between "AP" and active substance[, if applicable, with a spacer in between],
- 3) redox coupling of the product from step 2) with "P" by means of redox coupling.

14. The method according to claim 12 [or 13], wherein the redox coupling is carried out in an aqueous DMSO solution.

15. The method according to claim [any one of claims 12 to] 14, wherein a further purification step follows.

17. Use of a conjugate according to claim 1 [any one of claims 1 to 11] for the cell-specific, compartment-specific or membrane-specific transport of a desired active substance.

10/031<sup>4121-133</sup>505

531 Rec'd PCT/EP 15 JAN 2002

## APPENDIX B

Specification

## CROSS-REFERENCE TO RELATED APPLICATIONS

This application is filed under the provisions of 35 U.S.C. §371 and claims the priority of International Patent Application No. PCT/DE00/02346 filed July 14, 2000, which in turn claims priority of German Patent Application No. 199 33 492.7 filed July 16, 1999.

Claims

1. A conjugate for mediating a cell-specific, compartment-specific or membrane-specific transport, wherein the conjugate comprises the following components:

a transport mediator for the cell membrane,

a cell-specific, compartment-specific or membrane-specific address protein or peptide, and

an active substance to be transported.

2. The conjugate according to claim 1, wherein the transport mediator is a peptide or protein which can pass through the plasma membrane.

3. The conjugate according to claim 1, wherein the transport mediator is a member selected from the group consisting of: a penetratin, a penetratin derivative,

4. The conjugate according to claim 3, wherein one of the penetratins has the following sequence:

5. The conjugate according to claim, wherein the cell-specific, compartment-specific or membrane-specific address protein or peptide is selected from the group consisting of:

H<sub>3</sub>N<sup>+</sup>-Net-Met-Ser-Phe-Val-Ser-Leu-Leu-Leu-Val-Gly-Ile-Leu-Phe-Trp-Ala-Thr-Clu-Ala-Clu-Gln-Leu-Thr-Lys-Cys-Glu-Val-Phe-Gln;

$$\text{H}_2\text{N}-\text{Lys}-\text{Asp}-\text{Glu}-\text{Leu}-\text{COO}^-;$$

H<sub>3</sub>N<sup>+</sup>-Met-Leu-Ser-Leu-Arg-  
Gln-Ser-Ile-Arg-Phe-Phe-  
Lys-Pro-Ala-Thr-Arg-Thr-  
Leu-Cys-Ser-Ser-Arg-Tyr-  
Leu-Leu;

-Pro-Pro-Lys-Lys-Lys-Arg-Lys-

11

Lys-Val-(= nuclear  
localization sequence from  
SV4Q-T antigen);

for import into peroxisomes  $\text{H}_2\text{N-Ser-Lys-Leu-COO}^-$ ; and

for binding to cell membrane  $\text{H}_3\text{N}^+\text{-Gly-Ser-Ser-Lys-Ser-Lys-Pro-Lys-}$ .

6. The conjugate according to claim 5, wherein the sequence for the import into the nucleus has the following sequence:

$\text{H}_3\text{N}^+ \text{-Pro-Lys-Lys-Lys-Arg-Lys-Val.}$

7. The conjugate according to claim, wherein the active substance is selected from the group consisting of nucleic acids, proteins/peptides and/or chemical substances.

8. The conjugate according to claim 1, wherein the conjugate has the following structure:

transport mediator - address protein - active substance.

9. The conjugate according to claim 1, wherein a spacer is also present, if applicable.

10. The conjugate according to claim 9, wherein the spacer is located between the address protein and the active substance.

11. The conjugate according to claim 9, wherein the spacer is a member selected from the group consisting of: polylysine, polyethylene glycol or polyvinyl pyrrolidone.
12. A method of preparing a conjugate according to claim 1, comprising the steps of:
  - 1) synthesizing separate peptides of "P", "AP",
  - 2) forming a covalent bond between "AP" and active substance,
  - 3) redox coupling of the product from step 2) with "P" by means of redox coupling.
13. The method according to claim 12, wherein the peptide synthesis is carried out according to the known Merrifield method.
14. The method according to claim 12, wherein the redox coupling is carried out in an aqueous DMSO solution.
15. The method according to claim 14, wherein a further purification step follows.
16. The method according to claim 15, wherein purification takes place by means of HPLC.
17. Use of a conjugate according to claim 1 for the cell-specific, compartment-specific or membrane-specific transport of a desired active substance.
18. Use according to claim 17 for use in diagnosis and/or therapy.

19. The method according to claim 12, further comprising:  
synthesizing a spacer to be covalently bonded between "AP"  
and active substance.



7/PRTS

10031505 0703  
10/031505  
531 Rec'd PCT/PT 15 JAN 2002

K 2826

**Conjugate for Mediating Cell-Specific, Compartment-Specific  
or Membrane-Specific Transport of Active Substances**

The present invention relates to conjugates for mediating cell-specific, compartment-specific or membrane-specific transport of active substances. The invention also relates to methods of producing said conjugates and their use.

As is known, cellular membrane systems are largely impermeable to many substances (e.g. nucleic acids, proteins, chemical substances) which shall be introduced into a cell from outside. For the introduction of nucleic acids it is possible to penetrate cell membranes by physical processes (transfection in the case of eukaryotes, transformation in the case of prokaryotes) and biological processes (infection). In the case of transformation, i.e. the direct take-up of the naked nucleic acid by the cell, the cells are treated beforehand. Various methods are available to produce these "competent cells". Most methods are based on the observations made by Mandel and Higa (J. Mol. Biol. 53, pages 159-163 (1970)) who were the first to show that it is possible to substantially increase the yields occurring when lambda-DNA is taken up by bacteria in the presence of calcium chloride. This method was used successfully for the first time by Cohen et al. (Proc. Natl. Acad. Sci. U.S.A. 69, pages 2210-2214 (1972)) for plasmid DNA and has been improved by many modifications. Another transformation method is based on the observation that high-frequency alternating-current fields can break up cell membranes (electroporation). This technique can be utilized to insert naked DNA not only in prokaryotic cells but also

in eukaryotic cell systems (Weaver *et al.*, J. Cell Biochem. 51, pages 426-435 (1993)). Two very mild methods of introducing DNA into eukaryotic cells were developed by Sikes *et al.* (Hum. Gen. Therap. 5, pages 837-840 (1994)) and Yang *et al.* (Proc. Natl. Acad. Sci U.S.A. 87, pages 9568-9572 (1990)). They are based on the direct injection of the DNA into single cells (microinjection) and on the bombardment of a cell population using microprojectiles of tungsten on the surface of which the corresponding nucleic acid was bound (gene gun), respectively. In a progress parallel to the physical transformation of cells, biological infection methods have proved their efficiency. They comprise in particular the viral introduction of nucleic acids into cells (Chatterjee *et al.*, Science 258, pages 1485-1486 (1992); Cossett and Rusell, Gene Therapy 3, pages 946-956 (1996); Bilbao *et al.*, FASEB J. 11, pages 624-634 (1997)) and the liposome-mediated lipofection (Bennett *et al.*, J. Drug Targeting 5, pages 149-162 (1997)). Reference is also made to standard methods of the liposomal transport (Gao and Huang, Gene Therapy 2, pages 710-722 (1995); Akhtar *et al.*, Nucl. Acid. Res. 19, pages 5551-5559 (1991)) and poly-L-lysine formation (Leonetti *et al.*, Bioconj. Chem. 1(2), page 149 (1990) of active substances to be able to transport them into cells.

Despite the above-listed plurality of methods of passing through the cellular membrane systems, there is no universal method serving for introducing different active substances into cells. All of the above-mentioned physical and biochemical methods are artificial and non-physiological unless they make use of cell-immanent mechanisms. It is presently not yet certain that viruses used as transport vehicles are free of toxicity. They are often not effective and, in addition, they are detected by the immune system.

It was therefore the object of the present invention to provide a possibility of permitting the site-directed and specific introduction of active substances into cells and compartments. The following demands must be complied with in this connection:

- universal applicability
- cell-specific, compartment-specific and membrane-specific introduction behavior
- high degree of effectiveness
- low immunogenicity
- minimization of the infection risk
- sufficiently long residence time.

This object is achieved by the subject matters defined in the claims.

The inventors developed a conjugate comprising the following components:

- a transport mediator for the cell membrane ("P"),
- a cell-specific, compartment-specific or membrane-specific address protein or peptide ("AP"), and
- an active substance to be transported ("W").

The conjugate according to the invention is preferably composed as follows:

**P - AP - W**

More preferably it comprises a spacer ("SP"):

**P - AP - SP - W**

The transport mediator for the cell membrane (abbreviated as "P" above) is a peptide or protein which can penetrate the plasma membrane. The length of this peptide or protein is not subject to limitation as long as it has the above property. Examples of "P" are derived preferably from the penetratin family (Derossi *et al.*, 1998, Trends Cell Biol. 8, pages 84-87) or are transportan or parts thereof (Pooga *et al.*, The FASEB Journal (1998), Vol. 12, page 68 *et seq.*), those of the penetratin family being preferred. An example of "P" is a penetratin having the following sequence:

NH<sub>2</sub>-RQIKIWFQNRRMKWKK-  
(NH<sub>2</sub>-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-  
Trp-Lys-Lys)

Further examples of the transport protein "P" are as follows:

Viral transport protein  
PTD protein transduction domain (TAT/HIV-1)  
1-letter code H<sub>2</sub>N-YGRKKRRQRRR-COOH  
3-letter code H<sub>2</sub>N-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg

Bacterial transport molecule  
TP protein transport domain TP(Eco)  
1-letter code H<sub>2</sub>N-MTRQTFWHRIKH-COOH  
3-letter code H<sub>2</sub>N-Met-Thr-Arg-Gln-Thr-Phe-Trp-His-Arg-Ile-Lys-His

The select "P" sequence is produced biologically (purification of natural transport mediator proteins or cloning and expression of the sequence in a eukaryotic or prokaryotic expression system), preferably synthetically,

e.g. according to the established Merrifield method (Merrifield, J. Am. Chem. Soc. 85: 2149, 1963).


The selection of the address protein or peptide (abbreviated as "AP" above) depends on the membrane or membrane system which has to be penetrated and the target compartment of the cell (cytoplasm, nucleus, mitochondria, chloroplast, endoplasmic reticulum) or the cell organelle which shall be reached. The length of this address peptide or protein is not subject to limitation as long as it comprises the property of ensuring a cell-specific, compartment-specific or membrane-specific transport. For the introduction of active substances, in particular nucleic acids, "APs" are generally used which contain a cell-specific, compartment-specific or membrane-specific recognition signal, directing the attached active substance to its site of action. There are the "APs" to chose from which can transport active substances in the presence or absence of a membrane potential. The pure address sequence is usually sufficient for a transport into the cell compartment. However, it is also possible to chose "APs" which have a cell-specific or compartment-specific peptidase cleavage site. In the most favorable case, this cleavage site lies within the signal sequence but it can also be attached thereto by additional amino acids to ensure the cleavage of the address sequence after the target compartment is reached. The select "AP" sequence is produced biologically (purification of natural transport mediator proteins or cloning and expression of the sequence in a eukaryotic or prokaryotic expression system), preferably synthetically, e.g. according to the established Merrifield method (Merrifield, J. Am. Chem. Soc. 85: 2149, 1963). Examples of address proteins or peptides are as follows:

Import into the ER	H <sub>3</sub> N <sup>+</sup> -Met-Met-Ser-Phe-Val-Ser- Leu-Leu-Leu-Val-Gly-Ile-Leu- Phe-Trp-Ala-Thr-Glu-Ala-Glu- Gln-Leu-Thr-Lys-Cys-Glu-Val- Phe-Gln-
Reimport into the ER	H <sub>2</sub> N-Lys-Asp-Glu-Leu-COO <sup>-</sup>
Import into the mitochondria	H <sub>3</sub> N <sup>+</sup> -Met-Leu-Ser-Leu-Arg-Gln- Ser-Ile-Arg-Phe-Phe-Lys-Pro- Ala-Thr-Arg-Thr-Leu-Cys-Ser- Ser-Arg-Tyr-Leu-Leu
Import into the nucleus	-Pro-Pro-Lys-Lys-Lys-Arg-Lys- Val  H <sub>3</sub> N <sup>+</sup> -Pro-Lys-Lys-Lys-Arg-Lys- Val- (= <b>nuclear localisation</b> <b>sequence</b> from SV40-T antigen)
Import into peroxisomes	H <sub>2</sub> N-Ser-Lys-Leu-COO <sup>-</sup>
Binding to the cell membrane	H <sub>3</sub> N <sup>+</sup> -Gly-Ser-Ser-Lys-Ser-Lys- Pro-Lys

Furthermore, the conjugate may optionally contain a spacer (abbreviated as "SP" above) which is preferably located between the address protein/peptide and the active substance to be transported. However, it may also be located additionally or alternatively between the transport mediator and the address protein. The spacer serves for eliminating or positively influencing optionally existing steric interactions between the components. For example, the spacer may be selected from: polylysine, polyethylene glycol (PEG),

derivatives of poly-methacrylic acid or polyvinyl pyrrolidone (PVP).

A redox cleavage site, e.g. -cysteine-S-S-cysteine-O-N-H-, is preferably present between the transport mediator and the address protein/peptide. The binding forming between transport mediator and address protein is a redox coupling (mild cell-immanent bond by means of DMSO; Rietsch and Beckwith, 1998, Annu. Rev. Gent 32, pages 163-84):



The active substance or active agent (abbreviated as "W" above) is not subject to limitations. It can be chosen freely, depending on the effect which shall be produced in a cell. The active substance may be a diagnostic agent and/or a therapeutic agent. The conjugate may also comprise more than one active substance. The active substance may optionally be labeled, e.g. radioactively, with a dye, with biotin/avidin, etc. The active substance may be a nucleic acid, a protein or peptide, a chemical substance, etc. The next ones are mentioned by way of example: cDNA, genomic DNA, complete genes, regulatory elements, transcription factors, molecular probes, oligonucleotides, mRNA, mTRNA, antisense RNA, antisense oligonucleotides, plasmids, viral DNA, synthetic nucleotides, PNA (peptide nucleic acids), single amino acids and their derivatives, peptides, proteins, monoclonal and/or polyclonal antibodies, pharmaceutical active substances, chemotherapeutic agents, dyes, sensitizers, particles.

The conjugate elements "P" and "AP" are preferably synthesized synthetically according to the Merrifield method (Merrifield, J. Am. Chem. Soc. 85: 2149, 1963). The coupling

The conjugate is preferably synthesized in the following steps:

- The conjugates according to the invention have the advantage that irrespective of the kind and size of an active substance they can introduce it into cells and transport it into the desired cell compartment. Thus, an improvement of diagnostics and therapy in human and veterinary medicines and an application in scientific research can be anticipated. In particular, the gene therapy can expect a boom on account of the conjugates according to the invention since complete genes including their regulatory elements



become transportable. However, all of the other active substances can also be transported more specifically to the site of action by means of the conjugates according to the invention, which reduces the occurrence of undesired side effects. It was found that conjugates up to 25 MDa can be introduced into the cell interior. Moreover, apoptosis is often triggered, which might be a desired effect. The conjugates according to the invention distinguish themselves by a universal usability on account of their cell-specific, compartment-specific and membrane-specific introduction behavior.

The invention is described in more detail by means of the attached figures:

Figure 1 shows a conjugate according to the invention;

Figure 2 shows a general diagram of the Fmoc synthesis;

Figure 3 shows the results of the fluorescence correlation spectroscopy measurement using AT1 cells

A) conjugate concentration: 50 nM  
incubation period: 5 hours

B) conjugate concentration: 5 nM  
incubation period: 5 hours

C) conjugate concentration: 50 nM  
incubation period: 24 hours

D) conjugate concentration: 5 nM  
incubation period: 24 hours;

Figure 4 shows the concentration-dependent and time-dependent transport of rhodamine<sup>110</sup> (L)-penetratin/RPMI medium;

Penetratin sequence, NLS and spacer were synthesized separately according to the standard Fmoc method ("peptides", H.-D. Jakubke, *Chemie und Biologie Spektrum*, Akad. Verl. 1996, ISBN 3-8274-0000-7). The general diagram of the Fmoc synthesis is shown in figure 2. For synthesizing the different component sequences, the first Fmoc amino acid

The purified peptide components are treated together with 20 % aqueous DMSO solution at room temperature for 5 hours, an oxidative coupling of the components resulting. For example, rhodamine 110 is coupled to the spacer as active substance to be transported. This is done by acid amide coupling at the free  $\alpha$ -amino group of the lysine spacer. The complete conjugate is then purified by means of reversed-phase HPLC.

The further conjugates according to the invention were produced analogously:

Alexa™(L)-PTD<sup>(TAT/HIV-1)</sup>-S-S-(L)-NLS-KK<sup>(rhodamine110)</sup>-PNA

Alexa™(L)-TP<sup>(1AOP/ECO)</sup>-S-S-(L)-NLS-KK<sup>(rhodamine110)</sup>-PNA

PNA = NH<sub>2</sub>-TTA AGG AGG CTC COOH (Example of active substance)

Alexa 350 = dye (Molecular Probes, U.S.)

**Example 2: Introduction of a conjugate according to the invention into cells**

AT-1 (rat prostate carcinoma) and DU-145 (human prostate carcinoma, ATCC HTB-81) cells were cultured in RPMI 1640, supplemented with 10 % FCS, 2 mM glutamine, 100 U/min. penicillin, 100 µg/ml streptomycin.

For fluorescence correlation spectroscopy (FCS) AT-1 or DU-145 cells are grown on slides for 24 hours. Having changed the medium using dyestuff-free RPMI 1640 (without phenol red), the penetratin-containing conjugate of Example 1 (100 nM) is placed onto the cells using RPMI and incubated at 37°C and with 5 % CO<sub>2</sub> for 5, 24 or 48 hours. Thereafter, the conjugate-containing medium is removed and washed twice with 200 µl of dyestuff-free RPMI and then measured by means of FCS. Laser excitation takes place at 488 nm and emission at 538 nm.

The conjugate is pursued on its way into the nucleus. For this, a cell is selected and focused under the light microscope. Having focused and set the laser, 100-µm steps are used for passing through the cells, and fluorescence is measured in the form of flashes by photomultipliers. Here, large molecules and small molecules migrate at differing speeds. The number of molecules diffusing in an area of 100 µm each is detected. In this way, the size of the diffused

molecules can be determined by means of the duration of the signal. The accompanying diagram is shown in figure 3.

In another experiment, the kinetics by which the conjugate reaches the cytoplasm is determined by the same method. The AT-1 cells were again attached for 24 hours. The medium containing the conjugate was used as described above. However, in this case, the fluorescence signal was immediately measured by FCS.

FCS clearly showed a strong accumulation on the cell membrane after an incubation period of 5 hours. Diffusion could not be detected. Only minor amounts of conjugate could be found in the cell membrane after an incubation period of 24 hours. Attention was then attracted by an accumulation in the nucleus which became even more intense within the observation period of 48 hours.

For the purpose of control conjugates were used in which rhodamine 110 was only bound to either penetratin or NLS. They did not show the above-described effect of nucleus accumulation. If they succeeded at all in penetrating the cell, the conjugates were stopped at the cell membrane of nuclear envelope where they accumulated.

As described analogously above, all of the conjugates produced in Example 1 were studied as regards their time-dependent intracellular transport into the cytoplasm (Z) or the nucleus (N). However, differing from the above-mentioned incubation periods the incubation periods were 1, 3, 6, 10 and 24 hours. The results are shown in Table 1.

### **Example 3: Concentration-dependent transport**

The purpose of the study was to determine to what extent the concentration of the transport peptide <sup>rhodamine110</sup>(L)-penetratin/RPMI medium influences the cellular and nucleus-directed transport in terms of time as well. A comparison was made between the fluorescence of 20  $\mu$ M and 100  $\mu$ M final concentration of <sup>rhodamine110</sup>(L)-penetratin/RPMI medium. For this purpose, DU-145 cells were incubated at the indicated concentrations for 1, 6, 12, 24 and 48 hours. Thereafter, washing was carried out three times with RPMI (without penetratin), once with PBS and again with RPMI. Having provided the cells with slide covers, fluorescence was determined directly afterwards by means of CLSM (confocal laser scanning microscopy). The results are shown in figure 4. It follows therefrom that at a high concentration of over 20  $\mu$ M a non-specific transport takes place, which suggests cytotoxicity. However, in a lower concentration there is specific transport into the cytoplasm.

### **Example 4: Inhibition of the proliferation of AT-1 cells by introducing an anti-sense construct**

Peptide-conjugate constructs according to figure 6 were produced using the method described in Example 1 analogously. Here, the active substance was in one case a PNA having the sequence NH<sub>2</sub>-TAC TGC GAC TCC GG-COOH (anti-sense with respect to rats P2 promoter c-myc = PNA<sub>AS</sub>) and then a non-sense (random) sequence having the nucleotide sequence NH<sub>2</sub>-TTA AGG AGG CTC-COOH (=PNA<sub>NS</sub>).

AT-1 cells were cultured in RPMI 1640, supplemented using 10 % FCS, 2 mM glutamine, 100 U/min. penicillin,, 100  $\mu$ g/ml streptomycin.

AT-1 cells are grown on slides for 24 hours. Having changed the medium using dyestuff-free RPMI 1640 (without phenol red), the conjugates (100 nM) are placed onto the cells with RPMI each and incubated at 37°C and with 5 % CO<sub>2</sub> for 24, 48, 72 or 96 hours. Thereafter, the conjugate-containing medium is removed and washed twice with 200 µl dyestuff-free RPMI. The cell number of AT-1 cells is determined by means of the Coulter counting method.

Untreated AT-1 cells were used as a control. Unligated PNA<sub>AS</sub> represents another control. As described analogously above, these controls were incubated with the AT-1 cells.

The result of this experiment is shown in figure 7. The proliferation of AT-1 was only inhibited after the administration of the anti-sense construct, *i.e.* this shows clearly that penetration of the nucleus where the anti-sense sequence can display the desired effect takes only place by means of the construct according to the invention. Unligated anti-sense sequence is as ineffective as the control or a construct which cannot hybridize with one of the AT-1 sequences.

## Claims

1. A conjugate for mediating a cell-specific, compartment-specific or membrane-specific transport, wherein the conjugate comprises the following components:

- a transport mediator for the cell membrane,
- a cell-specific, compartment-specific or membrane-specific address protein or peptide, and
- an active substance to be transported.

2. The conjugate according to claim 1, wherein the transport mediator is a peptide or protein which can pass through the plasma membrane.

3. The conjugate according to claim 1 or 2, wherein the transport mediator is derived from the penetratin family or is transportan or parts thereof or is a bacterial or viral transport protein.

4. The conjugate according to claim 3, wherein one of the penetratins has the following sequence:

NH<sub>2</sub>-RQIKIWFQNRRMKWKK-

5. The conjugate according to any one of the preceding claims, wherein the cell-specific, compartment-specific or membrane-specific address protein or peptide is selected from the group consisting of:

for import into the ER

H<sub>3</sub>N<sup>+</sup>-Met-Met-Ser-Phe-Val-Ser-Leu-Leu-Leu-Val-Gly-Ile-Leu-Phe-Trp-Ala-Thr-Glu-Ala-Glu-Gln-Leu-Thr-Lys-Cys-Glu-Val-Phe-Gln-



for reimport into the ER	H <sub>2</sub> N-Lys-Asp-Glu-Leu-COO <sup>-</sup>
for import into mitochondria	H <sub>3</sub> N <sup>+</sup> -Met-Leu-Ser-Leu-Arg- Gln-Ser-Ile-Arg-Phe-Phe- Lys-Pro-Ala-Thr-Arg-Thr- Leu-Cys-Ser-Ser-Arg-Tyr- Leu-Leu
for import into the nucleus	-Pro-Pro-Lys-Lys-Lys-Arg- Lys-Val
	H <sub>3</sub> N <sup>+</sup> -Pro-Lys-Lys-Lys-Arg- Lys-Val- (= nuclear localisation sequence from SV40-T antigen)
for import into peroxisomes	H <sub>2</sub> N-Ser-Lys-Leu-COO <sup>-</sup>
for binding to cell membrane	H <sub>3</sub> N <sup>+</sup> -Gly-Ser-Ser-Lys-Ser- Lys-Pro-Lys-

6. The conjugate according to claim 5, wherein the sequence for the import into the nucleus has the following sequence:

H<sub>3</sub>N<sup>+</sup>-Pro-Lys-Lys-Lys-Arg-Lys-Val-

7. The conjugate according to any one of the preceding claims, wherein the active substance is selected from the group consisting of nucleic acids, proteins/peptides and/or chemical substances.
8. The conjugate according to any one of the preceding claims, wherein the conjugate has the following structure:

transport mediator - address protein - active substance



16. The method according to claim 15, wherein purification takes place by means of HPLC.
17. Use of a conjugate according to any one of claims 1 to 11 for the cell-specific, compartment-specific or membrane-specific transport of a desired active substance.
18. Use according to claim 17 for use in diagnosis and/or therapy.

**Abstract of the Disclosure**

The present invention relates to conjugates for mediating a cell-specific, compartment-specific or membrane-specific transport of active substances. The invention also relates to methods of preparing these conjugates as well as their use. The conjugates comprise:



- a transport mediator for the cell membrane,
- a cell-specific, compartment-specific or membrane-specific address protein or peptide, and
- an active substance to be transported.

Table 1

Time-dependent intracellular transport of the modules. (Z): cytoplasm; (N): nucleus;  
(+): positive signal; (-): no signal. Final conjugate concentration: 100 pM

Transporter	incubation period [h]	Z	N	method
Alexa <sup>TM</sup> (L)-Penet-S-S-(L)-NLS-KK <sup>(Rhod110)</sup> -PNA	1	+	+	CLSM
	3	+	+	
	6	+	+	
	10	membrane spots	+	
	24	membrane spots	+	
Alexa <sup>TM</sup> (L)-PTT <sup>(TAT/HIV-1)</sup> -S-S-(L)-KK <sup>(Rhod110)</sup> -PNA	1	+	-	CLSM
	3	+	-	
	10	+	-	
	24	-	-	
Alexa <sup>TM</sup> (L)-TP <sup>(1A0P/ECn)</sup> -S-S-(L)-NLS-KK <sup>(Rhod110)</sup> -PNA	1	+	+	CLSM
	3	+	+	
	6	+	+	
	10	-	+	
	24	-	+	
Alexa <sup>TM</sup> (L)-TP <sup>(1A0P/ECn)</sup> -S-S-(L)-KK <sup>(Rhod110)</sup> -PNA	1	+	-	CLSM
	3	+	-	
	6	+	-	
	10	-	-	
	24	-	-	

## PNA conjugate construct - Diagram




transport protein	cysteine	redox cleav.site	..	nuclear localization sequence	spacer specific sequence

Penetratin: P: (pAntp): RQIKIWFGQNRMRMKWKK-

NLS: (Nucl. Localis. Signal) PKKKRKV

Fig. 1

2/7



general diagram for Fmoc synthesis

Fig. 2

3/7

Cellular take-up of the conjugate according to the invention




Fig. 3






Fig. 4

## „Bioshuttle“ - Diagram of modular synthesis

Transport module -S-S- address module spacer active substance




Fig. 5

10/031505

6/7







Fig. 6

10/031505

7/7

# Proliferation AT-1




Fig. 7



DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION (continued)

ATTORNEY DOCKET NO. 421-133

2-00

Full Name of Second Inventor: Peter PeschkeCitizenship: GermanResidence: Maximilianstr. 16, D-67459 Bohl-Iggelheim, Germany DEXPost Office Address: Same

Inventor's Signature

Date

6/3/02

3-00

Full Name of Third Inventor: Eckart FriedrichCitizenship: GermanResidence: An den Hofwiesen 6, D-76831 Landau-Ilbesheim, Germany DEXPost Office Address: Same

Inventor's Signature

Date

March 6, 02

4-00

Full Name of Fourth Inventor: Rüdiger PipkornCitizenship: German SwedishResidence: Adolf-Rauch-Str. 3, D-69120 Heidelberg, Germany DEXPost Office Address: Same

Inventor's Signature

Date

9/3/02

5-00

Full Name of Fifth Inventor: Waldemar WaldeckCitizenship: GermanResidence: Tilsiter Str. 49, D-69514 Laudendach, Germany DEXPost Office Address: Same

Inventor's Signature

Date

5/3/2002

6-00

Full Name of Sixth Inventor: Jürgen DebusCitizenship: GermanResidence: Krenzstraße 11, D-76698 Stettfeld, Germany DEXPost Office Address: Same

Inventor's Signature

Date

7.3.2002